...lysine gingipain, a protease produced by the periodontitis-causing bacteria.Cortexyme’s...

...a futility analysis that would have been difficult to fail By selina koch, executive editor Cortexyme’s...
...agent failed to demonstrate overwhelming efficacy (p=0.005), a second goal of the interim analysis.Shares of Cortexyme Inc....
...periodontitis-causing bacteria, bringing a fresh approach to a disease in serious need of new ideas. Selina Koch COR388 Cortexyme Inc. Neurology Alzheimer's...

...Lebwohl as EVP and CMO. He was CMO of Semma Therapeutics Inc. Neurodegenerative diseases company Cortexyme Inc....
...He was CFO of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan...

...helped the company raise $156 million across three financings including an IPO on NASDAQ (see “Cortexyme’s...

...as exploratory endpoints in larger trials that could support subsequent use as a primary endpoint. Cortexyme Inc....
...secondary endpoints are physician-administered subjective tests of cognition. The partners first used Speech Assessment in Cortexyme’s...
...Assessment could be used as a primary endpoint. That timeline includes the readout from the Cortexyme...

...their IPO, with most also having substantial insider support in the IPO itself. For example, Cortexyme Inc....
...8% in May, Cortexyme had a massive first day pop, jumping $15.89 (93%) to $32.89. Cortexyme...
...NASDAQ:IDYA) 5/22/19 $57.5 $202.3 $201.5 0% Applied Therapeutics Inc. (NASDAQ:APLT) 5/13/19 $40.0 $170.5 $140.5 -18% Cortexyme Inc....

...increased their share price, with two other companies -- Turning Point Therapeutics Inc. (NASDAQ:TPTX) and Cortexyme Inc....

...volatile trading in May as trade tensions between the U.S. and China have escalated (see "Cortexyme's...

...a week that had five biotechs go public, four of which priced within range (see “Cortexyme’s...

...will be closely watched by the bolus of companies in the IPO queue. CNS company Cortexyme Inc....
...of Thursday’s session, while metabolic company Axcella Health Inc. (NASDAQ:AXLA) priced at the bottom end. Cortexyme...
...Industrial Average was off 2.1% during that period, and the NASDAQ Composite was off 3%. Cortexyme...